Veraxa Biotech AG - Post de-SPAC
VRXA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002079109
In the last 90 days, Veraxa Biotech AG - Post de-SPAC insiders filed 2 open-market purchases and 0 sales; 8 institutions reported holding it in 13F filings for Q2 2026, worth $599.6K in total; no superinvestor holds it.
Other share classesVRXAW
Holders of 5% or more of VRXA
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Veraxa Biotech AG - Post de-SPAC, largest stake first. The change is against the holder's previous filing.
No holder currently reports owning 5% or more of Veraxa Biotech AG - Post de-SPAC on Schedule 13D or 13G.
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
Schedule 13D and 13G filings on Veraxa Biotech AG - Post de-SPAC, newest first.
No Schedule 13D or 13G filings on Veraxa Biotech AG - Post de-SPAC are on file.
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Veraxa Biotech AG - Post de-SPAC shares.
No Form 144 notices for Veraxa Biotech AG - Post de-SPAC are on file.